
Through a strategic partnership with Invagen Pharmaceuticals Inc., Ranbaxy Laboratories Limited plans to market Zonisamide Capsules for the treatment of epilepsy in the market. Zonisamide is the USFDA-approved generic equivalent of the listed drug Zonegran™.
Under the agreement, products will be developed, submitted for FDA approval and manufactured by Invagen in its
Read more at Ranbaxy press release.



.jpg)



Comment Preview